ArticleTherapeutics and clinical risk management2008
Treating psoriasis with adalimumab.
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.American journal of clinical dermatology · 2022Trial
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Genomic profile of an IDH-wild-type glioblastoma diagnosed following TNF-α inhibitor therapy: a molecular case study.Frontiers in oncology · 2026Article
- Co-occurrence of endometriosis with psoriasis and psoriatic arthritis: Genetic insights (Review).Experimental and therapeutic medicine · 2025Review
- Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.Non-coding RNA · 2025Review
- Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.Journal of inflammation research · 2025Review
- Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.Recent advances in inflammation & allergy drug discovery · 2025Review
- A Rare Presentation of Erythrodermic Psoriasis.Cureus · 2024Article
- Inflammation and Psoriasis: A Comprehensive Review.International journal of molecular sciences · 2023Review
- The Current Advancement in Psoriasis.Cureus · 2023Review
- Potential Therapeutic Value of the STING Inhibitors.Molecules (Basel, Switzerland) · 2023Review
- Unconventional Therapy with IgY in a Psoriatic Mouse Model Targeting Gut Microbiome.Journal of personalized medicine · 2021Article
- Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.International journal of molecular sciences · 2021Review
- A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Observational
- New Treatment Addressing the Pathogenesis of Psoriasis.International journal of molecular sciences · 2020Review
- Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.World journal of gastroenterology · 2018Review
- Decreased A-to-I RNA editing as a source of keratinocytes' dsRNA in psoriasis.RNA (New York, N.Y.) · 2018Article
- Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Clinical, cosmetic and investigational dermatology · 2010Article
- Biologics in dermatologic therapy - an update.Indian journal of dermatology · 2009Article
- Biologics and Biosimilars in Psoriasis.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among the most successful strategies for treatment has been the use of biologic immunotherapies targeting tumor necrosis factor alpha (TNF). Recent research has evaluated the efficacy and safety of a new anti-TNF agent, adalimumab. Adalimumab is a human monoclonal antibody that is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of rheumatoid arthritis and psoriatic arthritis. Recently released data from large, randomized clinical trials suggests that adalimumab has significant efficacy for the treatment of chronic plaque psoriasis and is well tolerated. Thus, adalimumab seems to be a promising therapeutic approach for patients who suffer from moderate to severe plaque psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.